Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Innovent Combines PD-1 with Avastin Biosimilar in China HCC Trial

publication date: Feb 28, 2019

Innovent Biologics of Suzhou has dosed the first patient in a China Phase II/III combination trial that pairs Tyvyt®, Innovent's approved anti-PD-1 mAb, with its Avastin biosimilar as a first-line treatment for patients with advanced hepatocellular carcinoma (HCC). The ORIENT-32 trial will enroll 566 patients with HCC. It will compare the regimen to Bayer's Nexavar, the current standard of care for liver cancer. The new test follows a Phase Ib clinical trial of Tyvyt® as a monotherapy in patients with advanced HCC. More details....

Stock Symbol: (HK: 1801) (NYSE: BAY)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.